Literature DB >> 10935153

Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity.

A J Maxwell1, B Anderson, M P Zapien, J P Cooke.   

Abstract

The objective of this study was to investigate the vascular and biochemical effects of a formulated product in the form of a bar enriched with a combination of nutrients known to enhance the synthesis or activity of endothelium-derived nitric oxide (EDNO). Individuals with hypercholesterolemia manifest impaired flow-mediated vasodilation, which is largely due to a reduction in EDNO activity. Oral supplementation with large amounts (6-21 g/day) of L-arginine, the precursor of EDNO, have been shown to improve endothelium-mediated vasodilation in hypercholesterolemia. Such large doses are effective but may be impractical to take in capsule form. Accordingly, we have developed a nutrient bar enriched with L-arginine as well as other ingredients that additively enhance EDNO activity. A pilot study in 41 hypercholesterolemic individuals indicated that the bar was well tolerated, had no adverse effects on serum chemistries or lipid profile, and normalized endothelial vasodilator function. To definitively determine if the nutrient bar normalizes endothelial function, a double-blind, placebo-controlled study was performed. Flow-mediated endothelium-dependent vasodilation was assessed by high-resolution ultrasonography before and after 1 week of bar use (2 bars/day) in an additional group of 43 volunteer subjects (57 +/- 10 years old; 22 men, 21 women) with hypercholesterolemia. Subjects manifested an impaired flow-mediated vasodilation before the intervention. Vasodilator function in the active bar group improved to within a normal range (6.5 +/- 3% before to 10 +/- 5% after, P = 0.02; normal, 12 +/- 3%) and was significantly better (P < 0.01) than in the placebo bar group (7.1 +/- 3% before to 6.7 +/- 4% after). These findings reveal that use of a nutrient bar designed to enhance EDNO activity improves flow-mediated endothelium-dependent vasodilation in hypercholesterolemic individuals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10935153     DOI: 10.1023/a:1007886725480

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  10 in total

Review 1.  Assessing endothelial function as a risk factor for cardiovascular disease.

Authors:  Alan L Hinderliter; Melissa Caughey
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

2.  Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism.

Authors:  Toshio Hayashi; Teiji Esaki; Daigo Sumi; Tapan Mukherjee; Akihisa Iguchi; Gautam Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

Review 3.  The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.

Authors:  James Leiper; Manasi Nandi
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

4.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

5.  Altering dietary lysine:arginine ratio has little effect on cardiovascular risk factors and vascular reactivity in moderately hypercholesterolemic adults.

Authors:  Sonia Vega-López; Nirupa R Matthan; Lynne M Ausman; Scott V Harding; Todd C Rideout; Masumi Ai; Seiko Otokozawa; Alicia Freed; Jeffrey T Kuvin; Peter J Jones; Ernst J Schaefer; Alice H Lichtenstein
Journal:  Atherosclerosis       Date:  2009-12-05       Impact factor: 5.162

Review 6.  Cerebral endothelial function determined by cerebrovascular reactivity to L-arginine.

Authors:  Janja Pretnar-Oblak
Journal:  Biomed Res Int       Date:  2014-04-17       Impact factor: 3.411

7.  Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease.

Authors:  Stewart F Graham; Olivier P Chevallier; Christopher T Elliott; Christian Hölscher; Janet Johnston; Bernadette McGuinness; Patrick G Kehoe; Anthony Peter Passmore; Brian D Green
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

8.  L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial.

Authors:  Naseh Pahlavani; Mostafa Jafari; Omid Sadeghi; Masoud Rezaei; Hamid Rasad; Hossein Ali Rahdar; Mohammad Hasan Entezari
Journal:  F1000Res       Date:  2014-12-12

Review 9.  The Effects of L-Arginine in Hypertensive Patients: A Literature Review.

Authors:  Abdulkarim W Abukhodair; Walid Abukhudair; Mohammed S Alqarni
Journal:  Cureus       Date:  2021-12-17

Review 10.  Application of Metabolomics in Alzheimer's Disease.

Authors:  Jordan Maximillian Wilkins; Eugenia Trushina
Journal:  Front Neurol       Date:  2018-01-12       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.